http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ueno Masaki,Toriumi Emi,Yoshii Aki,Tabata Yuki,Furudate Takeshi,Tajima Yusuke 대한척추외과학회 2022 Asian Spine Journal Vol.16 No.3
Study Design: Retrospective cohort study.Purpose: To evaluate the efficacy of our current prophylactic strategy by investigating the incidence of subsequent vertebral body fractures (SVBFs) following balloon kyphoplasty (BKP).Overview of Literature: Although extensive studies have investigated the risk factors for SVBFs after BKP, few have reported on postoperative therapies to prevent SVBFs and have evaluated their effectiveness.Methods: This study enrolled 273 patients who underwent an initial BKP. To treat osteoporosis, parathyroid hormone (PTH) administration was started 1–2 weeks before BKP and continued for at least 6 months postoperatively. Corsets were applied for 3 months after the procedure. Rehabilitative interventions, including hip range-of-motion training, muscle strengthening exercises, and motion/posture instruction, were started from the preoperative assessment time point and resumed 3 hours postoperatively. Corsets were used in all patients. Therefore, no grouping based on corset use was performed. PTH was used in 180 patients, and they were divided into the following two groups: PTH user group and PTH nonuser group. Rehabilitative interventions were provided to all patients for a median duration of 17 days. Patients who underwent rehabilitative intervention for <17 and ≥17 days were included in the short-term and long-term intervention groups, respectively. The incidences of SVBFs for these four groups were compared.Results: SVBF occurred in 29 patients (10.6%). The SVBF incidence among patients who were prescribed all three prophylactic measures was 6.2%. The PTH user group had a significantly lower incidence of distant vertebral body fractures as compared to the PTH nonuser group. The long-term rehabilitation group had a significantly lower incidence of SVBFs and adjacent vertebral body fractures within 50 postoperative days than the short-term group.Conclusions: A 17-day or longer rehabilitative intervention may lower the risk of early adjacent vertebral body fractures, and the use of PTH may reduce the risk of distant vertebral body fractures.
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
( Ryohei Hayashi ),( Yoshitaka Ueno ),( Shinji Tanaka ),( Kana Onishi ),( Takeshi Takasago ),( Masaki Wakai ),( Toshikatsu Naito ),( Kensuke Sasaki ),( Shigehiro Doi ),( Takao Masaki ),( Kazuaki Chaya 대한장연구학회 2021 Intestinal Research Vol.19 No.4
Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal complication that can cause end-stage renal failure, but the frequency of this comorbidity has not been described. Thus, the aim of this study was to investigate the frequency of IgAN in patients with IBD. Methods: This study included 620 patients with IBD (338 with ulcer-ative colitis [UC] and 282 with Crohn’s disease [CD]) from the Hiroshima University Hospital outpatient department. IgAN cases were identified from medical interviews, blood examinations (serum immunoglobulin A), and urinalyses (occult blood, proteinuria). Definitive IgAN cases were diagnosed by renal biopsies, while those detected through the clinical course and test results, but not clinically recommended for renal biopsy, were defined as suspected IgAN. Results: We analyzed 427 cases meeting the inclusion criteria (220 with UC and 207 with CD). The incidence of IgAN across all patients with IBD was 3.0%. The frequency of IgAN was significantly higher in patients with CD (11/207, 5.3%) than in those with UC (2/220, 0.9%) (P< 0.01). Moreover, a significant correlation was found between CD patients with ileostomy or colostomy and a diagnosis of IgAN. Con-clusions: Patients with IBD present a high incidence of IgAN, especially those with CD who have undergone ileostomy or co-lostomy. (Intest Res 2021;19:430-437)
Low-Power 12-bit 160-MS/s Pipeline A/D Converters
Mai Nozawa,Daisuke Kurose,Takeshi Ueno,Tetsuro Itakura 대한전자공학회 2008 ITC-CSCC :International Technical Conference on Ci Vol.2008 No.7
Low-power 12-bit 160-MS/s pipeline A/D converters are designed for wireless receivers. Instead of using ultra-deep submicron devices of low supply voltage, we employ analog-option devices that operate at supply voltage of 2.5V in a 90-㎚ CMOS process. To achieve lower power dissipation, an I/Q amplifier sharing technique is employed. Furthermore, charge transfer level shifters are proposed in S/H circuits and MDACs for realizing class-AB operation. The area is 1.1㎟, the simulated power dissipation is 75㎽/channel and the simulated ENOB is 11.15bit.
Cytochrome P450 1B1 polymorphisms and risk of renal cell carcinoma in men.
Chang, Inik,Fukuhara, Shinichiro,Wong, Darryn K,Gill, Ankurpreet,Mitsui, Yozo,Majid, Shahana,Saini, Sharanjot,Yamamura, Soichiro,Chiyomaru, Takeshi,Hirata, Hiroshi,Ueno, Koji,Arora, Sumit,Shahryari, V Saikon Pub. Co 2014 TUMOR BIOLOGY Vol.35 No.10
<P>The cytochrome P450 1B1 (CYP1B1) enzyme activates xenobiotics to reactive forms as well as convert estradiol to 4-hydroxy-estradiol that has been shown to play a role in the carcinogenesis process of the kidney in male but not female animals. Prior reports show polymorphic variants of CYP1B1 to alter catalytic activity, and thus, we hypothesize that polymorphisms of the CYP1B1 gene are involved in the malignant transformation of the renal cell in men. The genetic distributions of five CYP1B1 polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism in 480 normal healthy subjects and 403 sporadic renal cell carcinoma cases. All subjects were Caucasian men. The sites evaluated were codons 48 (C??G, Arg??Gly, rs10012), 119 (G??T, Ala??Ser, rs1056827), 432 (C??G, Leu??Val, rs1056836), 449 (C??T, Asp, rs1056837), and 453 (A??G, Asn??Ser, rs1800440). A trend was demonstrated for the 432 Val/Val (χ2, P?=?0.06) and 449 T/T (χ2, P?=?0.1) genotypes to play a protective role against renal cancer. Odds ratio (95 % confidence interval) for Val/Val compared to Leu/Leu at codon 432 was 0.65 (0.44-0.95) and T/T compared to C/C at codon 449 was 0.67 (0.45-0.99). Codons 432 and 449 were observed to be linked (D?=?0.24), and haplotype involving 432 Val and 449 T was significantly reduced in cancer cases (P?=?0.04). No association was found, however, when analyzing polymorphic sites with clinical stage of cancer. These results demonstrate polymorphisms of CYP1B1 to be associated with renal carcinogenesis and are of importance in understanding their role in the pathogenesis of renal cell carcinoma.</P>
Yamada, Ikuhiro,Matsuyama, Masato,Ozaka, Masato,Inoue, Dai,Muramatsu, Yusuke,Ishii, Hiroshi,Junko, Ueda,Ueno, Makoto,Egawa, Naoto,Nakao, Haruhisa,Mori, Mitsuru,Matsuo, Keitaro,Nishiyama, Takeshi,Ohkaw Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.1
Background: We aimed to evaluate the role of genetic polymorphisms in tobacco carcinogen-metabolizing genes and their interactions with smoking in a hospital-based case-control study of Japanese subjects. Materials and Methods: We examine the associations of pancreatic cancer risk with genetic polymorphisms in GSTM1, GSTT1 and GSTP1, phase II enzymes that catalyze the conjugation of toxic and carcinogenic electrophilic molecules. The study population consisted of 360 patients and 400 control subjects, who were recruited from several medical facilities in Japan. Unconditional logistic regression methods were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between genotypes and pancreatic cancer risk. Results: Among the control subjects, the prevalence of the GSTM1-null genotype and the GSTT1-null genotype was approximately 56% and 48%, respectively. Cases and controls were comparable in terms of GSTM1 and GSTT1 genotype distributions. Neither of the deleted polymorphisms in GSTM1 and GSTT1 was associated with the risk of pancreatic cancer, with an age- and sex-adjusted OR of 0.99 (95%CI: 0.74-1.32) for the GSTM1-null genotype, and 0.98 (95%CI: 0.73-1.31) for the GSTT1-null genotype. The OR was 0.97 (95%CI: 0.64-1.47) for individuals with the GSTM1 and GSTT1-null genotypes compared with those with the GSTM1 and GSTT1- present genotypes. No synergistic effects of smoking or GST genotypes were observed. Conclusions: Our results indicate no overall association between the GSTM1 and GSTT1 deletion polymorphisms and pancreatic cancer risk in the Japanese subjects in our study.